Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An assessment of the effectiveness of Stellate Ganglion Block in alleviating symptoms of Long COVID-19.
We evaluated the treatment results of 41 patients (18 male and 23 female) aged between 18 and 89, who received Stellate Ganglion Block (SGB) with Ultrasound guidance for Long COVID-19 Syndrome. The patients were from the United States and received treatment at our Colorado clinics during the period of September to December 2022.Those who responded to our post-procedure follow-up calls were included in the study population.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SGB Patients for Long COVID 19 | Patients who received ultrasound guided Stellate Ganglion block for symptoms of Long COVID in our Colorado clinics. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stellate Ganglion Block | Procedure | Ultrasound guided block of the Stellate Ganglion with local anesthetics. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Symptom Response | Evaluation of the symptoms response to the Stellate Ganglion Block | 3 months |
Not provided
Not provided
Inclusion Criteria: People who scheduled themselves for a SGB in our clinics in Colorado.
-
Exclusion Criteria:
Stellate Ganglion Block Contraindications
-
Not provided
Not provided
Not provided
Not provided
The study included 18 male and 23 females with an age range between 18 and 89 who underwent stellate ganglion block (SGB) for long COVID-19 Syndrome.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lisa Pearson, DNAP | Metamorphosis LTD | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metamorphosis LTD | Cañon City | Colorado | 81212 | United States |
Plan to share data file
Within a month
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000094024 | Post-Acute COVID-19 Syndrome |
| D001342 | Autonomic Nervous System Diseases |
| D000086582 | Anosmia |
| D004408 | Dysgeusia |
| D005222 | Mental Fatigue |
| D063806 | Myalgia |
| D004417 | Dyspnea |
| D004244 | Dizziness |
| D003371 | Cough |
| D010146 | Pain |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009422 | Nervous System Diseases |
| D000857 | Olfaction Disorders |
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013651 | Taste Disorders |
| D005221 | Fatigue |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009468 | Neuromuscular Diseases |
| D059352 | Musculoskeletal Pain |
| D012120 | Respiration Disorders |
| D012818 | Signs and Symptoms, Respiratory |
Not provided
Not provided